Harmony Biosciences Holdings
$ 28.19
4.91%
24 Feb - close price
- Market Cap 1,623,641,000 USD
- Current Price $ 28.19
- High / Low $ 29.31 / 25.90
- Stock P/E 8.89
- Book Value 14.50
- EPS 3.17
- Next Earning Report 2026-03-03
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.13 %
- ROE 0.26 %
- 52 Week High 40.87
- 52 Week Low 25.52
About
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and markets therapies for patients with rare neurological disorders. The company is headquartered in Plymouth Meeting, Pennsylvania.
Analyst Target Price
$42.82
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-10-27 | 2025-08-05 | 2025-04-28 | 2025-02-20 | 2024-10-29 | 2024-08-06 | 2024-04-30 | 2024-02-22 | 2023-10-31 | 2023-08-01 | 2023-05-02 | 2023-02-21 |
| Reported EPS | 1.08 | 0.68 | 0.7785 | 1.08 | 0.79 | 0.2 | 0.67 | 0.45 | 0.75 | 0.56 | 0.66 | 0.79 |
| Estimated EPS | 0.8149 | 0.72 | 0.9136 | 0.8171 | 0.67 | -0.06 | 0.6 | 0.48 | 0.65 | 0.63 | 0.47 | 0.58 |
| Surprise | 0.2651 | -0.04 | -0.1351 | 0.2629 | 0.12 | 0.26 | 0.07 | -0.03 | 0.1 | -0.07 | 0.19 | 0.21 |
| Surprise Percentage | 32.5316% | -5.5556% | -14.7877% | 32.1748% | 17.9104% | 433.3333% | 11.6667% | -6.25% | 15.3846% | -11.1111% | 40.4255% | 36.2069% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-03 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 0.8611 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: HRMY
2026-02-24 13:52:29
Harmony Biosciences Holdings, Inc. has released its annual 10-K report, detailing robust financial results with net product revenue of $868.5 million and a net income of $158.7 million. The company is advancing its product pipeline, including WAKIX for narcolepsy and new acquisitions, while actively pursuing strategic initiatives like further pipeline expansion and capital management. Challenges include reliance on WAKIX, pricing pressures, and regulatory compliance, which management plans to address through portfolio diversification.
2026-02-24 12:52:29
Harmony Biosciences reported strong financial results for 2025, with WAKIX net product revenue reaching $868.5 million, a 22% increase year-over-year. The company reiterated its 2026 net revenue guidance for WAKIX at $1.0 - $1.04 billion, projecting it will achieve blockbuster status in narcolepsy. Harmony Biosciences is also advancing its pipeline with new formulations of pitolisant and other drug candidates, aiming to expand its reach into broader CNS indications and extend the pitolisant franchise beyond 2040.
2026-02-23 13:57:00
Harmony Biosciences (HRMY) stock fell approximately 10% after Deutsche Bank and Truist downgraded the company's rating. This downgrade was largely due to concerns over a potential negative outcome in an intellectual property case between Harmony Biosciences and AET Pharma US, specifically regarding Harmony's medication.
2026-02-23 13:19:53
Deutsche Bank has downgraded Harmony Biosciences (NASDAQ:HRMY) to Hold from Buy and lowered its price target due to increased patent risk for its lead drug Wakix. This follows a bench trial where a judge reportedly leaned negatively towards Harmony Biosciences regarding intellectual property challenges from AET Pharma, potentially accelerating Wakix's loss of exclusivity. Despite the legal uncertainty, the company recently reported strong preliminary net product revenue for Wakix and announced partnerships for new studies, with other analysts maintaining positive ratings based on promising trial data for other drug candidates.
2026-02-23 13:02:49
Deutsche Bank has downgraded Harmony Biosciences (NASDAQ: HRMY) to Hold from Buy and lowered its price target due to increased patent risk for its lead drug, Wakix. A recent bench trial indicated a negative outcome for Harmony Biosciences against a generics manufacturer, potentially accelerating Wakix's loss of exclusivity. Despite the legal uncertainty, the stock appears undervalued according to InvestingPro analysis, even as shares declined following the trial's conclusion.
2026-02-23 11:39:59
Deutsche Bank's analyst David Hoang has downgraded Harmony Biosciences Holdings Inc. (HRMY) to a Hold rating. The article, which appears to be a premium-only piece, gives no further details about the reasons for the downgrade without a subscription. The downgrade was updated on February 23, 2026, at 6:58 AM EST, while the initial report was at 6:39 AM EST.
